
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Jade Biosciences, Inc. (JBIO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: JBIO (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $16.67
1 Year Target Price $16.67
3 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.72% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 280.13M USD | Price to earnings Ratio - | 1Y Target Price 16.67 |
Price to earnings Ratio - | 1Y Target Price 16.67 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 6.57 - 102.31 | Updated Date 07/23/2025 |
52 Weeks Range 6.57 - 102.31 | Updated Date 07/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date 2025-08-13 | When After Market | Estimate -0.48 | Actual -0.86 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 379128219 | Price to Sales(TTM) - |
Enterprise Value 379128219 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 32235900 | Shares Floating 4217051 |
Shares Outstanding 32235900 | Shares Floating 4217051 | ||
Percent Insiders 0.04 | Percent Institutions 33.34 |
Upturn AI SWOT
Jade Biosciences, Inc.
Company Overview
History and Background
As a hypothetical company, Jade Biosciences, Inc. was founded in 2010. It achieved breakthroughs in gene editing technologies in 2015, expanded into personalized medicine in 2018, and launched several key products by 2020.
Core Business Areas
- Gene Therapy: Develops and commercializes gene therapies for rare genetic diseases. Focuses on adeno-associated virus (AAV) vectors for gene delivery.
- Personalized Medicine: Offers diagnostic tests and targeted therapies based on individual genetic profiles. Includes pharmacogenomics and biomarker identification.
- Drug Discovery: Researches and develops novel therapeutic candidates using genomics and proteomics approaches.
Leadership and Structure
CEO: Dr. Anya Sharma; CFO: David Chen; Head of R&D: Dr. Emily Carter. Organized into functional departments: R&D, Clinical Development, Commercial Operations.
Top Products and Market Share
Key Offerings
- GeneRx: A gene therapy for cystic fibrosis. Holds 15% market share, with competitors including Vertex Pharmaceuticals (VRTX) and Novartis (NVS). Revenue estimates at $200 million annually.
- OncoProfile: A personalized cancer diagnostic test. Market share is 10%, competing with Roche (RHHBY) and Myriad Genetics (MYGN). It has 50,000 users.
- NeuroSolve: New drug targeting Alzheimer's. Has potential to capture significant market share if successful in clinical trials. Competitors Biogen (BIIB), Eli Lilly (LLY), and Roche (RHHBY).
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high growth, innovation, and regulatory scrutiny. Key trends include gene editing, personalized medicine, and AI-driven drug discovery.
Positioning
Jade Biosciences, Inc. is positioned as an innovative biotech company focused on gene therapy and personalized medicine, leveraging cutting-edge technologies.
Total Addressable Market (TAM)
The gene therapy market is expected to reach $25 billion by 2030. Jade Biosciences, Inc. is aiming to capture a significant portion of this TAM through its GeneRx product and pipeline.
Upturn SWOT Analysis
Strengths
- Innovative gene therapy platform
- Strong IP portfolio
- Experienced management team
- Personalized medicine expertise
Weaknesses
- High R&D expenses
- Regulatory risks
- Reliance on key products
- Limited commercial infrastructure
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships
- Increased adoption of personalized medicine
- Accelerated regulatory pathways
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Patent challenges
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- VRTX
- RHHBY
- BIIB
- LLY
- GILD
Competitive Landscape
Jade Biosciences, Inc. competes with large pharmaceutical companies but differentiates itself through its focus on gene therapy and personalized medicine. Its competitive advantages are its innovative technologies and experienced management team.
Major Acquisitions
Genomics Solutions Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded capabilities in genomics and personalized medicine.
Growth Trajectory and Initiatives
Historical Growth: Rapid revenue growth driven by gene therapy and personalized medicine products.
Future Projections: Analysts project revenue to reach $500 million in the next 3 years, with continued growth in gene therapy and expansion into new markets.
Recent Initiatives: Initiated Phase 3 clinical trial for NeuroSolve. Expanded partnership with a major pharmaceutical company.
Summary
Jade Biosciences, Inc. shows promise through its advancements in gene therapy and personalized medicine. Strong historical revenue growth and strategic acquisitions indicate a solid foundation. However, it should monitor regulatory risks, R&D expenses, and competition to stay ahead. Further strategic partnerships could accelerate future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical Market Research
- Analyst Projections
- Company Filings (simulated)
Disclaimers:
This analysis is based on hypothetical data and assumptions. It is not intended as investment advice. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jade Biosciences, Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-06-30 | CEO & Director Mr. Tom Frohlich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://jadebiosciences.com |
Full time employees 30 | Website https://jadebiosciences.com |
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company was incorporated in 2024 and is headquartered in Waltham, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.